Notably, while the EP300 upregulation observed in the full cohort was attenuated under this restriction, its partner gene CEBPB retained a robust and highly significant increase (Supplementary Fig.
← all excerpts
Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.
1
—
—